-
公开(公告)号：US12092634B2
公开(公告)日：2024-09-17
申请号：US17046200
申请日：2019-04-10
CPC分类号： G01N33/5306 , G01N33/6869 , G01N2333/54
摘要： Methods and compositions for detecting and quantifying cytokines are provided. The disclosed assays have reduced assay interference relative to commercially available assays and/or a control assay. The interference can be cytokine dependent, cytokine independent, or both. One embodiment provides an IL-33 immunoassay that reduces assay interference caused by endogenous soluble IL-33 binding molecules present in the sample. Exemplary soluble IL-33 binding molecules include, but are not limited to anti-IL-33 antibodies, soluble ST2 receptor, and serum components. In some embodiments a blocking agent is added to the sample to reduce, inhibit, or block IL-33 complexes in the sample from reforming after acid dissociation of the IL-33 complexes in the sample. In one embodiment, the blocking agent and the detection reagent do not compete for binding to IL-33.
-
公开(公告)号：US20230110651A1
公开(公告)日：2023-04-13
申请号：US17954999
申请日：2022-09-28
发明人： Jihua Chen , Kimberly Kendra , Stacey Shank , Lisa DeStefano , Matthew Andisik , Michael Partridge , Albert Torri , Giane Oliveira Sumner
摘要： The present invention generally pertains to methods of determining concentrations of drugs and their targets. In particular, the present invention, in part, pertains to use of a mild acidic assay condition to determine total drug and total target concentrations to mitigate either target interference or drug interference. The present invention also discloses a free target assay using a capture agent that has a lower affinity with a much slower association and dissociation rate compared to the drug.
-
公开(公告)号：US20220260577A1
公开(公告)日：2022-08-18
申请号：US17734688
申请日：2022-05-02
IPC分类号： G01N33/574 , G01N33/50
摘要： The present invention generally pertains to methods of testing the concentration of therapeutic proteins and testing for the presence of anti-drug antibodies (ADAs) against therapeutic proteins. In particular, the present invention pertains to the use of mitigating agents against interfering competing drugs in ligand binding assays or cell-based assays for the quantification of therapeutic proteins and detection of anti-drug antibodies and neutralizing antibodies against therapeutic proteins.
-
公开(公告)号：US20210341487A1
公开(公告)日：2021-11-04
申请号：US17245271
申请日：2021-04-30
IPC分类号： G01N33/574 , G01N33/50
摘要： The present invention generally pertains to methods of testing for the presence of neutralizing antibodies (NAbs) against therapeutic proteins. In particular, the present invention pertains to the use of mitigating agents against interfering competing drugs in ligand binding assays or cell-based assays for the detection of neutralizing antibodies against therapeutic proteins.
-
公开(公告)号：US10261094B2
公开(公告)日：2019-04-16
申请号：US15031126
申请日：2014-10-30
摘要： A immunogenicity assay for detecting the presence of neutralizing antibodies to a biotherapeutic protein wherein the biotherapeutic protein has been administered to a patient in need, comprising the steps of (a) obtaining a sample from the patient; (b) incubating the sample in the presence of a capture reagent; and (c) adding a detecting reagent, wherein a decreased signal relative to a control sample indicates the presence of a neutralizing antibody to the biotherapeutic agent.
-
公开(公告)号：US11448651B2
公开(公告)日：2022-09-20
申请号：US16507880
申请日：2019-07-10
IPC分类号： G01N33/577 , C07K16/28 , C07K16/42 , G01N33/53
摘要： The present disclosure is directed towards modifying binding molecules in order to minimize pre-existing binding interactions, including binding molecules engineered to minimize or mitigate background reactivity in a sample matrix caused by drug non-specific binding interactions.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.015 秒)
